KPTI Quote, Financials, Valuation and Earnings

Bruker Corp. has a net margin of -75.21% compared to Karyopharm Therapeutics, Inc.'s net margin of -6.8%. Karyopharm Therapeutics, Inc.'s return on equity of -- beat Bruker Corp.'s return on equity of -1.2%.

Karyopharm Therapeutics, Inc. has a consensus price target of $14.67, signalling upside risk potential of 132.44%. On the other hand Bruker Corp. has an analysts' consensus of $54.07 which suggests that it could grow by 11.74%. Given that Karyopharm Therapeutics, Inc. has higher upside potential than Bruker Corp., analysts believe Karyopharm Therapeutics, Inc. is more attractive than Bruker Corp..

Karyopharm Therapeutics, Inc. has a beta of 0.207, which suggesting that the stock is 79.284% less volatile than S&P 500. In comparison Bruker Corp. has a beta of 1.169, suggesting its more volatile than the S&P 500 by 16.854%.

Karyopharm Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bruker Corp. offers a yield of 0.41% to investors and pays a quarterly dividend of $0.05 per share. Karyopharm Therapeutics, Inc. pays -- of its earnings as a dividend. Bruker Corp. pays out 26.44% of its earnings as a dividend. Bruker Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Karyopharm Therapeutics, Inc. quarterly revenues are $44M, which are smaller than Bruker Corp. quarterly revenues of $860.5M. Karyopharm Therapeutics, Inc.'s net income of -$33.1M is higher than Bruker Corp.'s net income of -$58.5M. Notably, Karyopharm Therapeutics, Inc.'s price-to-earnings ratio is -- while Bruker Corp.'s PE ratio is 77.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Karyopharm Therapeutics, Inc. is 0.38x versus 2.14x for Bruker Corp.. Usually stocks with elevated PS ratios are considered overvalued.

IDEXX Laboratories, Inc. has a net margin of -75.21% compared to Karyopharm Therapeutics, Inc.'s net margin of 24.85%. Karyopharm Therapeutics, Inc.'s return on equity of -- beat IDEXX Laboratories, Inc.'s return on equity of 66.88%.

Karyopharm Therapeutics, Inc. has a consensus price target of $14.67, signalling upside risk potential of 132.44%. On the other hand IDEXX Laboratories, Inc. has an analysts' consensus of $766.00 which suggests that it could grow by 7.08%. Given that Karyopharm Therapeutics, Inc. has higher upside potential than IDEXX Laboratories, Inc., analysts believe Karyopharm Therapeutics, Inc. is more attractive than IDEXX Laboratories, Inc..

Karyopharm Therapeutics, Inc. has a beta of 0.207, which suggesting that the stock is 79.284% less volatile than S&P 500. In comparison IDEXX Laboratories, Inc. has a beta of 1.671, suggesting its more volatile than the S&P 500 by 67.09%.

Karyopharm Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IDEXX Laboratories, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Karyopharm Therapeutics, Inc. pays -- of its earnings as a dividend. IDEXX Laboratories, Inc. pays out -- of its earnings as a dividend.

Karyopharm Therapeutics, Inc. quarterly revenues are $44M, which are smaller than IDEXX Laboratories, Inc. quarterly revenues of $1.1B. Karyopharm Therapeutics, Inc.'s net income of -$33.1M is lower than IDEXX Laboratories, Inc.'s net income of $274.6M. Notably, Karyopharm Therapeutics, Inc.'s price-to-earnings ratio is -- while IDEXX Laboratories, Inc.'s PE ratio is 56.71x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Karyopharm Therapeutics, Inc. is 0.38x versus 14.00x for IDEXX Laboratories, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Krystal Biotech, Inc. has a net margin of -75.21% compared to Karyopharm Therapeutics, Inc.'s net margin of 81.15%. Karyopharm Therapeutics, Inc.'s return on equity of -- beat Krystal Biotech, Inc.'s return on equity of 19.91%.

Karyopharm Therapeutics, Inc. has a consensus price target of $14.67, signalling upside risk potential of 132.44%. On the other hand Krystal Biotech, Inc. has an analysts' consensus of $273.60 which suggests that it could fall by -4.01%. Given that Karyopharm Therapeutics, Inc. has higher upside potential than Krystal Biotech, Inc., analysts believe Karyopharm Therapeutics, Inc. is more attractive than Krystal Biotech, Inc..

Karyopharm Therapeutics, Inc. has a beta of 0.207, which suggesting that the stock is 79.284% less volatile than S&P 500. In comparison Krystal Biotech, Inc. has a beta of 0.463, suggesting its less volatile than the S&P 500 by 53.705%.

Karyopharm Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Krystal Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Karyopharm Therapeutics, Inc. pays -- of its earnings as a dividend. Krystal Biotech, Inc. pays out -- of its earnings as a dividend.

Karyopharm Therapeutics, Inc. quarterly revenues are $44M, which are smaller than Krystal Biotech, Inc. quarterly revenues of $97.8M. Karyopharm Therapeutics, Inc.'s net income of -$33.1M is lower than Krystal Biotech, Inc.'s net income of $79.4M. Notably, Karyopharm Therapeutics, Inc.'s price-to-earnings ratio is -- while Krystal Biotech, Inc.'s PE ratio is 42.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Karyopharm Therapeutics, Inc. is 0.38x versus 22.79x for Krystal Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

TG Therapeutics, Inc. has a net margin of -75.21% compared to Karyopharm Therapeutics, Inc.'s net margin of 19.97%. Karyopharm Therapeutics, Inc.'s return on equity of -- beat TG Therapeutics, Inc.'s return on equity of 145.71%.

Karyopharm Therapeutics, Inc. has a consensus price target of $14.67, signalling upside risk potential of 132.44%. On the other hand TG Therapeutics, Inc. has an analysts' consensus of $44.86 which suggests that it could grow by 46.74%. Given that Karyopharm Therapeutics, Inc. has higher upside potential than TG Therapeutics, Inc., analysts believe Karyopharm Therapeutics, Inc. is more attractive than TG Therapeutics, Inc..

Karyopharm Therapeutics, Inc. has a beta of 0.207, which suggesting that the stock is 79.284% less volatile than S&P 500. In comparison TG Therapeutics, Inc. has a beta of 1.865, suggesting its more volatile than the S&P 500 by 86.494%.

Karyopharm Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TG Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Karyopharm Therapeutics, Inc. pays -- of its earnings as a dividend. TG Therapeutics, Inc. pays out -- of its earnings as a dividend.

Karyopharm Therapeutics, Inc. quarterly revenues are $44M, which are smaller than TG Therapeutics, Inc. quarterly revenues of $161.7M. Karyopharm Therapeutics, Inc.'s net income of -$33.1M is lower than TG Therapeutics, Inc.'s net income of $390.9M. Notably, Karyopharm Therapeutics, Inc.'s price-to-earnings ratio is -- while TG Therapeutics, Inc.'s PE ratio is 11.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Karyopharm Therapeutics, Inc. is 0.38x versus 9.29x for TG Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.